Direct Biologics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Direct Biologics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Direct Biologics: 7 sponsored US clinical trials, 2 recruiting.
Direct Biologics sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Perianal Fistula Due to Crohn's Disease, with 1 trials.
Upper-quartile sponsor footprint
Direct Biologics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease
NCT06918808
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
NCT05354141
DB-3Q for the Treatment of Medically Refractory Crohn's Disease
NCT07625293
Study of ExoFlo for the Treatment of Perianal Fistulas
NCT05836883
Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease
NCT05130983
Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
NCT05176366
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
NCT04493242
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Direct Biologics pipeline
2 recruiting of 7 indexed (29% open); 1 completed (14%).
Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Perianal Fistula Due to Crohn's Disease (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Direct Biologics: open-pipeline peers nationwide
Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
Direct Biologics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
- Alnylam Pharmaceuticals · 29% recruiting · 49 trials
- Annovis Bio · 29% recruiting · 7 trials
Related
What to do with this Direct Biologics page
7 registered trials is a research-attention snapshot, not an endorsement of Direct Biologics or any single study.
- 2 of Direct Biologics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Perianal Fistula Due to Crohn's Disease is the condition Direct Biologics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Perianal Fistula Due to Crohn's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Direct Biologics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.